

ONLINE FILING

February 4, 2020

The Secretary, National Stock Exchange of India Ltd., Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai -400 051	The Secretary, BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001.
--	---

Sub: **Outcome of Board Meeting held on 4th February, 2020 and announcements pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations')**

Dear Sir,

Pursuant to the provisions of the Listing Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held today, commenced at 12:00 noon, has considered and approved, inter alia, the following:

- (i) Un-audited Financial Results (Standalone and Consolidate) of the Company for the quarter/ nine months ended 31st December, 2019.
The Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter/ nine months ended 31st December, 2019, prepared in terms of Regulation 33 of the Listing Regulations together with Limited Review Reports of the Statutory Auditors of the Company are enclosed herewith.
- (ii) Appointment of Dr. Devlina Chakravarty as Managing Director of the Company for a term of 5 (Five) years w.e.f. 1st April, 2020 to 31st March, 2025.
- (iii) Seeking Shareholders Approval through postal ballot for following items:
 - a) Appointment of Dr. Devlina Chakravarty as Managing Director;
 - b) Continuation/ Appointment of Mr. Ugar Sain Anand as an Independent Director of the Company beyond the age of 75 years;
 - c) Appointment of Mr. Sunil Tandon as an Independent Director of the Company;
 - d) Loan to Subsidiary of the Company.

The meeting of the Board of Directors was concluded at 2.50 PM.

The necessary disclosure in terms of Para A of Part A of Schedule III of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as Annexure – 1 hereto with respect to new appointment on the Board.

This is for your information and records.

Thanking you,

Yours faithfully,
for Artemis Medicare Services Ltd.,


(Rakesh Kumar Kaushik)
Company Secretary & Compliance Officer
Membership No. 9929

Annexure 1

S.NO	Detail of event that need to be provided	Information of Such Event		
		Dr. Devlina Chakravarty	Mr. Ugar Sain Anand	Mr. Sunil Tandon
1.	Reason for Change	Appointment of Dr. Devlina Chakravarty as Managing Director of the Company.	Continuation/ Appointment of Mr. Ugar Sain Anand through shareholders approval	Appointment of Mr. Ugar Sain Anand through shareholders approval
2.	Date of Appointment/Re-Appointment	1 st April, 2020	10 th October 2019	10 th October 2019
3.	Term of Appointment	For 5 (Five) years with effect from 1 st April, 2020 to hold office up to 31 st March, 2025, Subject to the Shareholders Approval vide special resolution through postal ballot.	For 1 (One Year) w.e.f. October 10, 2019.	For 1 (One Year) w.e.f. October 10, 2019
4.	Disclosure of relationship between director	Dr. Devlina Chakravarty is not related to any Director of the Company.	Mr Ugar Sain Anand is not related to any Director of the Company.	Mr. Sunil Tandon is not related to any Director of the Company.

Brief Profiles:

(a) Dr. Devlina Chakravarty

Dr. Devlina Chakravarty started her career in 1993 as a radiologist trained from Mumbai University. She did fellowships/ preceptorship programmes from University of Berlin (Germany), UCLA (Los Angeles) and Brigham & Women (Boston) in Head and Neck & Body Imaging. She worked as senior faculty and Programme Director in Radiology in different reputed hospitals in Delhi before joining Artemis in 2007. She strongly believes in ethical practices in healthcare and quality of service. She believes private hospitals can make "profits" without "profiteering." She is a process and system driven person and believes strongly in "quality" and "efficiency" in healthcare. Good medical outcomes, patient safety, infection control and antimicrobial resistance are something close to her heart over and above creating great working environments for doctors and all other staff, through a transparent system of management. "Personalized tertiary care" with "service excellence" is her motto. Her dream is to create the most prestigious hospital in India with cutting edge technology, best in class professionals, medical education, ethical and transparent practices.



♦ **Artemis Hospital (A unit of Artemis Medicare Services Ltd.)**

♦ Sector 51, Gurugram - 122001, Haryana, India. Ph.: +91-124-4511 111 | Fax: +91-124-4588 899

♦ **Emergency & Trauma: +91-124-4588 888**

NABH & JCI Accredited

Registered Office: Plot No. 14, Sector 20, Dwarka, New Delhi - 110075 | Corporate Office: Artemis Hospital, Sector 51, Gurugram - 122001, Haryana, India

CIN: U85110DL2004PLC126414 | GST: 06AAFCOA0130M1Z1(HR), 07AAFCOA0130M1ZZ(DEL) | TAN: DDLA16048E | PAN: AAFCA0130M | Email: info@artemishospitals.com

ARTEMIS
PHR AP



(b) Mr. Ugar Sain Anand

Mr. Ugar Sain Anand, is a Chartered Accountant, with over 38 years of experience. He joined the Board of Directors of the Company in the year 2019. His experience is focused in the areas of Accounts, Finance, Taxation and Business development.

(c) Mr. Sunil Tandon

Mr. Sunil Tandon is a Mechanical Engineer from Delhi College of Engineering (1975 batch) and an MBA with top honours & a gold medal from FMS (1977 batch), University of Delhi. He has started his career with Engineers India Ltd. a premier Engineering design consultancy, where he had the opportunity of working with International Engineering design companies like Toyo, Snam Progetti etc. Thereafter, Mr. Sunil Tandon has changed over to commercial aspects of business, including Purchase & Project exports at Ballarpur Industries Ltd, followed by a stint as Executive Asstt. to Vice Chairman at Modi Alkalies & Chemicals with exposure to diverse functions.



◆ Artemis Hospital (A unit of Artemis Medicare Services Ltd.)

◆ Sector 51, Gurugram - 122001, Haryana, India. Ph.: +91-124-4511 111 | Fax: +91-124-4588 899

◆ **Emergency & Trauma: +91-124-4588 888**

NABH & JCI Accredited

Registered Office: Plot No. 14, Sector 20, Dwarka, New Delhi - 110075 | Corporate Office: Artemis Hospital, Sector 51, Gurugram - 122001, Haryana, India

CIN: U85110DL2004PLC126414 | GST: 06AAFCA0130M1Z1(HR), 07AAFCA0130M1ZZ(DEL) | TAN: DELA16048E | PAN: AAFCA0130M | Email: info@artemishospitals.com

ARTEMIS
PHR APP

Scan to Download



ARTEMIS MEDICARE SERVICES LIMITED

Plot No.14, Sector 20, Dwarka, South West Delhi, Delhi- 110075

Ph.: +91-124-4511111; Fax: +91-124-4588899; Email: info@artemishospitals.com; Web site: www.artemishospitals.com

CIN: L85110DL2004PLC126414

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2019

(₹ In Lakhs)

S No.	Particulars	Artemis Medicare Services Limited					
		Quarter ended			Nine Months ended		Year ended
		31-Dec-19 (Unaudited)	30-Sep-19 (Unaudited) (recast as per Note 3)	31-Dec-18 (Unaudited) (recast as per Note 3)	31-Dec-19 (Unaudited) (recast as per Note 3)	31-Dec-18 (Unaudited) (recast as per Note 3)	31-Mar-19 (Audited) (recast as per Note 3)
1.	Income						
	(a) Revenue from Operations	14,277.32	14,725.47	13,903.84	42,573.55	40,635.89	54,651.59
	(b) Other Income	70.90	122.98	62.59	251.48	268.93	400.21
	Total Income	14,348.22	14,848.45	13,966.43	42,825.03	40,904.82	55,051.80
2.	Expenses						
	(a) Purchases of Pharmacy drugs & Medical consumables	3,425.28	3,584.39	3,279.35	10,378.75	9,591.70	12,940.94
	(b) Purchases of Stock in Trade	36.11	46.96	34.71	113.63	111.33	145.16
	(c) Changes in Inventories of Pharmacy drugs, Medical consumables & Stock In Trade	(18.68)	(51.26)	19.08	(79.40)	(50.50)	(27.72)
	(d) Employee Benefits Expense	2,614.16	2,526.58	2,504.94	7,632.71	7,198.09	9,715.95
	(e) Finance Costs	295.18	344.71	309.58	967.40	811.46	1,099.71
	(f) Depreciation and Amortization Expense	565.64	562.74	501.73	1,673.61	1,487.55	2,007.39
	(g) Other Expenses	6,535.77	6,879.99	6,353.94	19,608.60	19,194.89	25,466.14
	Total Expenses	13,453.46	13,894.11	13,003.33	40,295.30	38,344.52	51,347.57
3.	Profit before Exceptional Items and Tax (1-2)	894.76	954.34	963.10	2,529.73	2,560.30	3,704.23
4.	Exceptional Items	-	-	-	-	-	-
5.	Profit before Tax (3-4)	894.76	954.34	963.10	2,529.73	2,560.30	3,704.23
6.	Tax Expense:						
	(a) Current Tax	153.71	417.08	333.72	857.93	1,041.03	1,377.75
	(b) Earlier Year Tax (Refer Note 3)	(381.57)	-	-	(381.57)	-	-
	(c) Deferred Tax	554.33	(47.49)	137.93	458.84	27.82	257.86
	Total Tax Expense	326.47	369.59	471.65	935.20	1,068.85	1,635.61
7.	Profit for the Period (5-6)	568.29	584.75	491.45	1,594.53	1,491.45	2,068.62
8.	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss						
	(a) Gains / (Losses) on defined benefit plans	(9.14)	0.11	(2.66)	(23.19)	(7.99)	(56.65)
	(b) Deferred Tax adjustment on revaluation	7.62	7.16	6.78	22.87	20.33	27.11
	(c) Income Tax relating to items that will not be reclassified to profit or loss in subsequent periods	3.19	(0.04)	0.93	8.10	2.79	19.79
	Total Other Comprehensive Income/(Loss) for the period, net of Income Tax	1.67	7.23	5.05	7.78	15.13	(9.75)
9.	Total Comprehensive Income/(Loss) ('OCI') (7+8)	569.96	591.98	496.50	1,602.31	1,506.58	2,058.87
10.	Equity Share Capital						
	(a) Paid up Equity Share Capital (Face value Rs. 10/- each)	1,323.77	-	-	1,323.77	-	-
	(b) Equity Share Capital Suspense Account (Face value Rs. 10/- each)	-	1,323.77	1,323.77	-	1,323.77	1,323.77
11.	Other Equity Excluding Revaluation Reserves (as per Balance Sheet of previous accounting year)	-	-	-	-	-	21,474.25
12.	Earning per Equity Share (Face value Rs. 10/- each)						
	(a) Basic	4.29*	4.42*	3.71*	12.05*	11.27*	15.63
	(b) Diluted	4.29*	4.42*	3.71*	12.05*	11.27*	15.63

* Not annualised



olk

Notes:-

1. The above standalone unaudited financial results for the quarter and nine months ended December 31st, 2019 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on February 4th, 2020. The statutory auditors of the Company have conducted a limited review of the said financial results.
2. Effective April 1st, 2019, the Company has adopted Ind AS 116 "Leases" and applied the same to all lease contracts existing as on April 1st, 2019 retrospectively with the cumulative effect of initially applying the standard recognised at the date of initial application, with right of use asset being recognized at an amount equal to the lease liability, adjusted by the prepaid lease rent. This has resulted in the net impact of increase in depreciation and finance cost by Rs. 24.28 Lakhs and Rs. 35.03 Lakhs respectively for the quarter ended December 31st, 2019 and Rs. 72.84 Lakhs and Rs. 105.02 Lakhs respectively for the nine months ended December 31st, 2019 and a decrease in lease rent cost of Rs. 34.41 Lakhs for the quarter ended December 31st, 2019 and Rs. 102.14 Lakhs for the nine months ended December 31st, 2019 in the Statement of Profit and Loss.
3. The Hon'ble National Company Law Tribunal, Delhi Bench, has approved the Composite Scheme of Amalgamation (Scheme) between "the Company and its Holding Company i.e. Artemis Health Sciences Ltd, its ultimate holding company i.e. Artemis Global Life Sciences Ltd and its fellow subsidiary company i.e. Athena Eduspark Limited." on September 30th, 2019. The Company has filed copy of the order with Registrar of companies Delhi on October 14th, 2019. The Company has accounted for the merger under the pooling of Interest method retrospectively for all the periods as described in Ind AS 103- Business Combinations of entities under common control. Accordingly financial results for the quarter ended September 30th, 2019 and nine months ended December 31st, 2019, quarter and nine months ended December 31st, 2018, and year ended March 31st, 2019 has been recast to reflect the impact of merger on standalone unaudited financial results of the Company and consequently provision for Income Tax has been calculated considering the effect of merger. Equity Share Capital Suspense Account amounting to Rs. 1323.77 Lakhs represents 1,32,37,700 Equity Shares of Rs 10/- each fully paid up pending allotment to the shareholders of Artemis Global Life Sciences Limited pursuant to the Composite Scheme of Amalgamation coming into effect. These equity shares have been issued to the shareholders of Artemis Global Life Sciences Limited on October 26th, 2019. The equity shares pending for allotment for the previous periods have been considered for the purpose of calculation of EPS appropriately.
4. As per the Scheme, the entire pre-scheme Paid-up Equity Share Capital of the Company was cancelled and according to the Scheme, the Company had issued and allotted an aggregate of 1,32,37,700 Equity Shares to the Shareholders of Artemis Medicare Services Limited (earlier shareholders of Artemis Global Life Sciences Limited) which got listed and commenced trading on BSE Limited and National Stock Exchange of India Limited on and from January 23rd, 2020 and consequently these results are first results prepared and approved as per SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended.
5. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended (Ind AS), as prescribed under Section 133 of the Companies Act 2013, and the other recognised accounting practices and policies to the extent applicable.
6. The Company is evaluating the impact of Section 115BAA of the Income Tax Act 1961, Introduced by the Taxation Laws (Amendment) Ordinance 2019, effective from financial year 2019-20.
7. Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period classification / disclosures.

Place : Gurugram
Dated : February 4th, 2020



For and on behalf of the Board of Directors
of Artemis Medicare Services Limited

Onkar S. Kanwar
Chairman & Director

A handwritten signature of Onkar S. Kanwar in blue ink. To the right of the signature is a circular blue stamp of Artemis Medicare Services Ltd. The text "Artemis Medicare Services Ltd." is written around the perimeter of the stamp, with a star at the bottom.

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Artemis Medicare Services Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Artemis Medicare Services Limited** ("the Company"), for the quarter ended December 31, 2019 and year to date from April 01, 2019 to December 31, 2019 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Other Offices

505, 5th Floor, Tower B, World Trade Tower
Sector 16, Noida- 201301
T: +91-120-4814400

4/18, Asaf Ali Road,
New Delhi-110002
T: +91 - 11 - 23274888/77410

B-XIX-220, Rani Jhansi Road, Ghumar Mandi
Ludhiana -121001
T: +91 - 161 - 2774527 • F: +91 - 161 - 2771618

5. As described in Note 3 of the Statement, effect of the merger of Artemis Health Sciences Limited (AHSL), Artemis Global Life Sciences Limited (AGLSL) and Athena Eduspark Limited (AEL) with the Artemis Medicare Services Limited has been accounted retrospectively for all periods presented being a common control transaction. Financial information of AHSL, AGLSL and AEL included in the accompanying Statement for the quarter ended December 31, 2018, year to date from April 01, 2018 to December 31, 2018 and the year ended March 31, 2019 was reviewed/ audited by the respective companies' predecessor auditors who have expressed an unmodified conclusion/ opinion on those financial information/ statements.

For SCV & CO. LLP
Chartered Accountants
Firm's Registration Number : 000235N/N500089



(RAJIV PURI)
PARTNER

MEMBERSHIP No. 084318

ICAI UDIN No. 200 84318 AAAAAA M 7295

PLACE : Gurugram

DATED : 04th February, 2020

ARTEMIS MEDICARE SERVICES LIMITED

Plot No.14, Sector 20, Dwarka, South West Delhi, Delhi- 110075

Ph.: +91-124-4511111; Fax: +91-124-4588899; Email: info@artemishospitals.com; Web site: www.artemishospitals.com

CIN: L85110DL2004PLC126414

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2019

(₹ in Lakhs)

S No.	Particulars	Artemis Medicare Services Limited					
		Quarter ended			Nine Months ended		Year ended
		31-Dec-19 (Unaudited)	30-Sep-19 (Unaudited) (recast as per Note 4)	31-Dec-18 (Unaudited) (recast as per Note 4)	31-Dec-19 (Unaudited) (recast as per Note 4)	31-Dec-18 (Unaudited) (recast as per Note 4)	31-Mar-19 (Audited) (recast as per Note 4)
1.	Income						
	(a) Revenue from Operations	14,349.96	14,733.98	13,903.84	42,654.70	40,635.89	54,651.59
	(b) Other Income	71.59	123.64	62.59	254.24	268.93	400.21
	Total Income	14,421.55	14,857.62	13,966.43	42,908.94	40,904.82	55,051.80
2.	Expenses						
	(a) Purchases of Pharmacy drugs & Medical consumables	3,476.51	3,588.94	3,279.35	10,434.53	9,591.70	12,940.94
	(b) Purchases of Stock in Trade	36.11	46.96	34.71	113.63	111.33	145.16
	(c) Changes In Inventories of Pharmacy drugs, Medical consumables & Stock In Trade	(41.37)	(52.57)	19.08	(103.40)	(50.50)	(27.72)
	(d) Employee Benefits Expense	2,646.68	2,545.33	2,504.94	7,698.58	7,198.09	9,728.18
	(e) Finance Costs	306.80	349.66	309.58	983.97	811.46	1,099.71
	(f) Depreciation and Amortization Expense	576.92	567.81	501.73	1,690.12	1,487.55	2,007.43
	(g) Other Expenses	6,567.57	6,898.77	6,353.94	19,660.69	19,194.89	25,483.63
	Total Expenses	13,569.22	13,944.90	13,003.33	40,478.12	38,344.52	51,377.33
3.	Profit before Exceptional Items and Tax (1-2)	852.33	912.72	963.10	2,430.82	2,560.30	3,674.47
4.	Exceptional Items	-	-	-	-	-	-
5.	Profit before Tax (3-4)	852.33	912.72	963.10	2,430.82	2,560.30	3,674.47
6.	Tax Expense:						
	(a) Current Tax	153.71	417.08	333.72	857.93	1,041.03	1,377.75
	(b) Earlier Year Tax (Refer Note 4)	(381.57)	-	-	(381.57)	-	-
	(c) Deferred Tax	521.26	(42.56)	137.93	430.73	27.82	257.86
	Total Tax Expense	293.40	374.52	471.65	907.09	1,068.85	1,635.61
7.	Profit for the Period (5-6)	558.93	538.20	491.45	1,523.73	1,491.45	2,038.86
8.	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss						
	(a) Gains / (Losses) on defined benefit plans	(9.14)	0.11	(2.66)	(23.19)	(7.99)	(56.65)
	(b) Deferred Tax adjustment on revaluation	7.62	7.16	6.78	22.87	20.33	27.11
	(c) Income Tax relating to Items that will not be reclassified to profit or loss in subsequent periods	3.19	(0.04)	0.93	8.10	2.79	19.79
	Total Other Comprehensive Income/(Loss) for the period, net of Income Tax	1.67	7.23	5.05	7.78	15.13	(9.75)
9.	Total Comprehensive Income/(Loss) ('OCI') (7+8)	560.60	545.43	496.50	1,531.51	1,506.58	2,029.11
10.	Profit / (Loss) for the year attributable to :						
	Shareholders of the Company	562.24	553.79	491.45	1,547.84	1,491.45	2,049.27
	Non-Controlling Interest	(3.31)	(15.59)	-	(24.11)	-	(10.41)
11.	Total Comprehensive Income / (Loss) for the period attributable to :						
	Shareholders of the Company	563.91	561.02	496.50	1,555.62	1,506.58	2,039.52
	Non-Controlling Interest	(3.31)	(15.59)	-	(24.11)	-	(10.41)
12.	Equity Share Capital						
	(a) Paid up Equity Share Capital (Face value Rs. 10/- each)	1,323.77	-	-	1,323.77	-	-
	(b) Equity Share Capital Suspense Account (Face value Rs. 10/- each)	-	1,323.77	1,323.77	-	1,323.77	1,323.77
13.	Other Equity Excluding Revaluation Reserves (as per Balance Sheet of previous accounting year)	-	-	-	-	-	21,447.98
14.	Earning per Equity Share (Face value Rs. 10/- each)						
	(a) Basic	4.25*	4.18*	3.71*	11.69*	11.27*	15.48
	(b) Diluted	4.25*	4.18*	3.71*	11.69*	11.27*	15.48

* Not annualised



Handwritten signature/initials

Notes:-

1. The above consolidated unaudited financial results for the quarter and nine months ended December 31, 2019 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on February 4th, 2020. The statutory auditors of the Company have conducted limited review of the said financial results.

2. The consolidated unaudited financial results includes the results of the Company and one subsidiary. The Company together with its subsidiary is herein referred to as the Group. The Subsidiary Company was incorporated on January 14th, 2019 accordingly the consolidated financial results for the quarter and nine months ended December 31st, 2018 are same as of the standalone financial results of the Parent Company.

3. Effective April 1st, 2019, the Group has adopted Ind AS 116 "Leases" and applied the same to all lease contracts existing as on April 1st, 2019 retrospectively with the cumulative effect of initially applying the standard recognised at the date of initial application, with right of use asset being recognized at an amount equal to the lease liability, adjusted by the prepaid lease rent. This has resulted in the net impact of increase in depreciation and finance cost by Rs. 24.28 Lakhs and Rs. 35.03 Lakhs respectively for the quarter ended December 31st, 2019 and Rs. 72.84 Lakhs and Rs. 105.02 Lakhs respectively for the nine months ended December 31st, 2019 and a decrease in lease rent cost of Rs. 34.41 Lakhs for the quarter ended December 31st, 2019 and Rs. 102.14 Lakhs for the nine months ended December 31st, 2019 in the Statement of Profit and Loss.

4. The Hon'ble National Company Law Tribunal, Delhi Bench, has approved the Composite Scheme of Amalgamation (Scheme) between "the Parent and its Holding Company i.e. Artemis Health Sciences Limited, its ultimate Holding Company i.e. Artemis Global Life Sciences Limited and its fellow Subsidiary Company i.e. Athena Eduspark Limited." on September 30th, 2019. The Parent Company has filed copy of the order with Registrar of Companies Delhi on October 14th, 2019. The Parent Company has accounted for the merger under the pooling of interest method retrospectively for all the periods as described in Ind AS 103-Business Combinations of entities under common control. Accordingly financial results for the quarter ended September 30th, 2019 and nine months ended December 31st, 2019, quarter and nine months ended December 31st, 2018, and year ended March 31st, 2019 has been recast to reflect the impact of merger on consolidated unaudited financial results of the Parent Company and consequently provision for Income Tax has been calculated considering the effect of merger.

Equity Share Capital Suspense Account amounting to Rs. 1323.77 Lakhs represents 1,32,37,700 Equity Shares of Rs 10/- each fully paid up pending allotment to the shareholders of Artemis Global Life Sciences Limited pursuant to the Composite Scheme of Amalgamation coming into effect. These equity shares have been issued to the shareholders of Artemis Global Life Sciences Limited on October 26th, 2019. The equity shares pending for allotment for the previous periods have been considered for the purpose of calculation of EPS appropriately.

5. As per the Scheme, the entire pre-scheme Paid-up Equity Share Capital of the Parent Company was cancelled and according to the Scheme, the Parent Company had issued and allotted an aggregate of 1,32,37,700 Equity Shares to the Shareholders of Artemis Medicare Services Limited (earlier shareholders of Artemis Global Life Sciences Limited) which got listed and commenced trading on BSE Limited and National Stock Exchange of India Limited on and from January 23rd, 2020 and consequently these results are first results prepared and approved as per SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended.

6. Segment Reporting at Consolidated level**Business segment**

The Group's operation predominantly comprise of only one business segment- Income from Healthcare Services.

Geographical information

Geographical information analyses the Group's revenue by the Group's country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been based on the geographical location of the customers.

Region	Quarter ended			Nine Months ended		Year ended
	31-Dec-19	30-Sep-19	31-Dec-18	31-Dec-19	31-Dec-18	31-Mar-19
India	9,272.17	9,186.63	8,413.96	27,498.72	24,430.09	33,342.29
Outside India	5,077.79	5,547.35	5,489.88	15,155.98	16,205.80	21,309.30
Total	14,349.96	14,733.98	13,903.84	42,654.70	40,635.89	54,651.59

(₹ in Lakhs)

Region	Carrying amount of Non-Current Assets					
	Quarter ended			Nine Months ended		Year ended
	31-Dec-19	30-Sep-19	31-Dec-18	31-Dec-19	31-Dec-18	31-Mar-19
India	46,517.30	45,518.42	39,307.03	46,517.30	39,307.03	43,892.55
Outside India	-	-	-	-	-	-
Total	46,517.30	45,518.42	39,307.03	46,517.30	39,307.03	43,892.55

7. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended (Ind AS), as prescribed under Section 133 of the Companies Act 2013, and the other recognised accounting practices and policies to the extent applicable.

8. Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period classification/disclosures.

For and on behalf of the Board of Directors
of Artemis Medicare Services Limited

Onkar S. Kanwar
Onkar S. Kanwar
Chairman & Director

Place : Gurugram
Dated : February 4th, 2020



Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Artemis Medicare Services Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Artemis Medicare Services Limited** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), for the quarter ended December 31, 2019 and year to date from April 01, 2019 to December 31, 2019 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

S.No. Name of the Company

1. Artemis Medicare Services Limited

Name of the Subsidiary

1. Artemis Cardiac Care Private Limited (incorporated on January 14, 2019)



Other Offices

505, 5th Floor, Tower B, World Trade Tower
Sector 16, Noida- 201301
T: +91-120-4814400

4/18, Asaf Ali Road,
New Delhi-110002
T: +91 - 11 - 23274888/77410

B-XIX-220,Rani Jhansi Road, Ghumar Mandi
Ludhiana -121001
T: +91 - 161 - 2774527 • F: +91 - 161 - 2771618

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. As described in Note 4 of the Statement, effect of the merger of Artemis Health Sciences Limited (AHSL), Artemis Global Life Sciences Limited (AGLSL) and Athena Eduspark Limited (AEL) with the Artemis Medicare Services Limited has been accounted retrospectively for all periods presented being a common control transaction. Financial information of AHSL, AGLSL and AEL included in the accompanying Statement for the quarter ended December 31, 2018 and year to date from April 01, 2018 to December 31, 2018 and the year ended March 31, 2019 was reviewed/ audited by the respective Companies' predecessor auditors who have expressed an unmodified conclusion/ opinion on those financial information/ statements. Our conclusion is not modified in respect of this matter.

For SCV & CO. LLP
Chartered Accountants
Firm's Registration Number : 000235N/N500089



(RAJIV PURI)
PARTNER
MEMBERSHIP No. 084318
ICAI UDIN No. 20084318AAAAAN1350

PLACE : Gurugram
DATED : 04th February, 2020